Status:

RECRUITING

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

Lead Sponsor:

EtiraRx Australia Pty Ltd

Conditions:

Advanced Solid Tumor

Metastatic Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.

Detailed Description

The goal of this open-label, dose escalation and cohort expansion Phase 1 clinical trial is to determine the safety, tolerability and pharmacokinetics of ERX-315 in patients with advanced solid tumors...

Eligibility Criteria

Inclusion

  • Patients must be at least 18 years of age at the time of signing the informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
  • Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Adequate baseline organ function and hematologic function
  • Life expectancy \>3 months

Exclusion

  • Systemic anti cancer therapy within 4 weeks of first dose of study drug
  • Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
  • Uncontrolled intercurrent illnesses
  • Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.

Key Trial Info

Start Date :

October 14 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2026

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT06533332

Start Date

October 14 2024

End Date

June 30 2026

Last Update

September 18 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Macquarie University Health

Ryde, New South Wales, Australia, 2109

2

The Kinghorn Cancer Center

Sydney, New South Wales, Australia, 2010

3

Cancer Research SA

Adelaide, South Australia, Australia, 5000

4

Icon Cancer Centre Adelaide

Adelaide, South Australia, Australia, 5037

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | DecenTrialz